Table 2.
Coverage indicators and domestic and Gavi financing mix for the expanded programme on immunization (EPI)
| Vaccine coverage (%)a | Expenditure for EPI (USD million (% of total))e | Co-financing share for pentavalent vaccine (%)g,h | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | Gavi funding timelines | DTP3 | HepB3 | Cases per 100,000 population for incidence of diphtheriab | Cases per 100,000 population for incidence of whooping coughc | Cases per 100,000 population for incidence of tetanusd | Domesticf | Gavi | UN agencies | Total | Gavi | Domestic | |
| 2003 | Gavi funding initiation | Hepatitis B | 98 | 32 | 0 | 0.6 | 0.60 | 1.09 (68.6) | 0.50 (31.4) | 0.00 (0.0) | 1.60 (100.0) | – | – |
| 2004 | 92 | 62 | 0 | 0.2 | 0.60 | 2.27 (77.5) | 0.66 (22.5) | 0.00 (0.0) | 2.93 (100.0) | – | – | ||
| 2005 | 96 | 87 | 0 | 0.4 | 0.60 | 1.25 (59.2) | 0.86 (40.8) | 0.00 (0.0) | 2.11 (100.0) | – | – | ||
| 2006 | 94 | 91 | 0 | 0.2 | 0.01 | 1.39 (64.4) | 0.77 (35.6) | 0.00 (0.0) | 2.16 (100.0) | – | – | ||
| 2007 | 93 | 91 | 0 | 0.1 | 0.00 | 0.69 (58.0) | 0.50 (42.0) | 0.00 (0.0) | 1.20 (100.0) | – | – | ||
| 2008 | Pentavalent vaccine | 91 | 91 | 0 | 0.1 | 0.01 | 2.52 (29.3) | 6.08 (70.7) | 0.00 (0.0) | 8.60 (100.0) | 100 | 0 | |
| 2009 | 88 | 88 | 0 | 0.2 | 0.00 | 1.09 (51.9) | 1.01 (48.1) | 0.00 (0.0) | 2.10 (100.0) | 0 | 0 | ||
| 2010 | 92 | 92 | 0 | 0.1 | 0.00 | 1.38 (21.7) | 4.98 (78.3) | 0.00 (0.0) | 6.36 (100.0) | 87 | 13 | ||
| 2011 | Gavi accelerated transition | 94 | 94 | 0 | 0.3 | 0.00 | 1.59 (25.9) | 4.54 (74.1) | 0.00 (0.0) | 6.13 (100.0) | 79 | 21 | |
| 2012 | 100 | 100 | 0 | 0.3 | 0.00 | 1.27 (31.5) | 2.76 (68.5) | 0.00 (0.0) | 4.03 (100.0) | 71 | 29 | ||
| 2013 | 97 | 97 | 0 | 0.3 | 0.00 | 2.37 (42.5) | 3.21 (57.5) | 0.00 (0.0) | 5.58 (100.0) | 81 | 19 | ||
| 2014 | 99 | 99 | 0 | 0.4 | 0.00 | 4.32 (86.9) | 0.61 (12.3) | 0.04 (0.8) | 4.96 (100.0) | 11 | 89 | ||
| 2015 | 99 | 99 | 0 | 0.5 | 0.00 | 4.09 (75.0) | 1.30 (23.9) | 0.06 (1.1) | 5.44 (100.0) | 4 | 96 | ||
| 2016 | Post-Gavi period commences | 97 | 98 | 0 | 0.3 | 0.00 | 7.72 (99.1) | 0.04 (0.5)i | 0.03 (0.4) | 7.79 (100.0) | – | – | |
| 2017 | 96 | 96 | 0 | 0.1 | 0.00 | 4.80 (72.3) | 1.82 (27.4)i | 0.02 (0.3) | 6.64 (100.0) | – | – | ||
| 2018 | 96 | 96 | 0 | 0.05 | 0.00 | 5.22 (93.7) | 0.33 (5.9)i | 0.02 (0.4) | 5.56 (100.0) | – | – | ||
| 2019 | 98 | 98 | 0 | 0.2 | 0.00 | 5.66 (92.5) | 0.42 (6.8)i | 0.04 (0.7) | 6.11 (100.0) | – | – | ||
| 2020 | 96 | 96 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | – | – | ||
WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) https://www.who.int/publications/m/item/wuenic_input, [accessed 13 February 2023].
Annual Health Bulletin 2019 http://www.health.gov.lk/moh_final/english/others.php?pid=110, [accessed 20 February 2023].
Annual Health Bulletin 2019 http://www.health.gov.lk/moh_final/english/others.php?pid=110, [accessed 20 February 2023].
Annual Health Bulletin 2019 http://www.health.gov.lk/moh_final/english/others.php?pid=110, [accessed 20 February 2023].
Expenditure data from Institute for Health Policy (IHP) Sri Lanka Health Accounts Database. Expenditure for 2019 is provisional.
Domestic financing includes expenditure for vaccines and injection safety supplies in the national immunization schedule, but excludes expenditures for human resources for delivery of immunization services and management of the EPI, cold chain maintenance and other expenditures.
Authors’ calculation using IHP Sri Lanka Health Account Database and Gavi annual progress reported 2008–2014 (https://www.gavi.org/country-documents/sri-lanka).
Sri Lanka initiated pentavalent vaccine administration on 1 January 2008 but suspended on 29 April 2008 following several deaths after administration of the vaccine. Following an investigation, the pentavalent vaccine was reintroduced in February 2010. This explains the absence of co-financing in 2009.
Gavi funding from 2015–2019 for IPV, 2017—HPV initiation grant and new vaccine support.
N/A indicates not available.